Dr. Kevin Curran
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Acute Lymphoblastic Leukemia
Studies T-Lymphoblastic Leukemia/Lymphoma
8 reported clinical trials
6 drugs studied
Area of expertise
1Acute Lymphoblastic Leukemia
CD19 positive
Stage II
Stage I
2T-Lymphoblastic Leukemia/Lymphoma
Stage II
Stage I
TP53 positive
Affiliated Hospitals
Clinical Trials Kevin Curran is currently running
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
Tabelecleucel
for EBV Associated Diseases
This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.
Recruiting1 award Phase 22 criteria
More about Kevin Curran
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Kevin Curran has experience with
- Tisagenlecleucel
- Tabelecleucel
- Personalized RATG (P-rATG)
- Cyclophosphamide
- Modified T Cells
- Modified T-cells
Breakdown of trials Kevin Curran has run
Acute Lymphoblastic Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Lymphoid Leukemia
Epstein-Barr Virus Infection
LGL Lymphoproliferative Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kevin Curran specialize in?
Kevin Curran focuses on Acute Lymphoblastic Leukemia and T-Lymphoblastic Leukemia/Lymphoma. In particular, much of their work with Acute Lymphoblastic Leukemia has involved CD19 positive patients, or patients who are Stage II.
Is Kevin Curran currently recruiting for clinical trials?
Yes, Kevin Curran is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Kevin Curran has studied deeply?
Yes, Kevin Curran has studied treatments such as Tisagenlecleucel, Tabelecleucel, Personalized rATG (P-rATG).
What is the best way to schedule an appointment with Kevin Curran?
Apply for one of the trials that Kevin Curran is conducting.
What is the office address of Kevin Curran?
The office of Kevin Curran is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.